All-oral shorter treatment regimens for multidrug- and rifampicin- resistant TB (MDR/RR-TB): A single arm prospective observational cohort study evaluating their effectiveness and safety for patients in Sierra Leone

Principal investigator

Lynda Foray
Purpose of study
Purpose of study

To determine the effectiveness and safety of all-oral shorter MDR/RR-TB regimens of 9-12 month duration under operational research conditions in Sierra Leone.

  • Concept
  • Protocol & ERB
  • Implementation
  • Completion
  • Archived

Study timeline

  • Title changed by Holly Baker

    17th December 2021

    Changed to “All-oral shorter treatment regimens for multidrug- and rifampicin- resistant TB (MDR/RR-TB): A single arm prospective observational cohort study evaluating their effectiveness and safety for patients in Sierra Leone”

  • Implementation
    23rd August 2021
  • ERB documentation added by Jodie Pearlman

    11th April 2021
    MSF_ERB_approval_protocol_2066_26Mar21.pdf
    98.2 KB
     
  •  
  • Protocol & ERB
    10th April 2021
  • Protocol accepted by ERB Updated by Jodie Pearlman

    9th April 2021  
  • Concept
    9th April 2021
  • Study created

    9th April 2021

    Originally titled All-oral shorter treatment regimens for multidrug- and rifampicinresistant TB (MDR/RR-TB): A single arm prospective observational cohort study evaluating their effectiveness and safety for patients in Sierra Leone

Publications

No publications recorded